Is CGEM or CHRS more undervalued in 2026?

CirclFi compares Cullinan Therapeutics, Inc. (CGEM) and Coherus Oncology, Inc. (CHRS) using 13 institutional-grade valuation models. CGEM has a Quality of Company score of 4.4/10 while CHRS scores 6.8/10.

Which is a better buy — CGEM or CHRS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CGEM and CHRS valuations compare?

CGEM at $16.44 and CHRS at $1.59 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CGEM vs CHRS Valuation Comparison 2026 — Intrinsic Value Analysis

CGEM

Biological Products, (No Diagnostic Substances)

Cullinan Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$16.44

Last close

Models

7/13

Active

CHRS

Biological Products, (No Diagnostic Substances)

Coherus Oncology, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$1.59

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	CGEM Fair Value	CGEM Upside	CHRS Fair Value	CHRS Upside
Bayesian DCF	Intrinsic	$4.42	-73.1%	$0.53	-66.6%
Earnings Power Value	Intrinsic	—	—	$9.90	+450.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.71	-89.6%	$0.47	-73.6%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CGEM vs CHRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CGEM vs CHRS — Which Stock Is More Undervalued?

CHRS scores higher with a 6.8/10 quality rating vs CGEM's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cullinan Therapeutics, Inc. (CGEM) and Coherus Oncology, Inc. (CHRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CGEM currently trades at $16.44 with a QOC of 4.4/10, while CHRS trades at $1.59 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).